PRESS RELEASE · Technology and Supply
Release date
TFA Details Antcin A Material Supply for TFA-01 Formulation and Studies
Approximately 100 kilograms of cultured material per month; internal batches with consistent Antcin A content of at least 3,000 ppm by dry weight
- TFA reports cultured material supply capacity of approximately 100 kilograms per month, along with Antcin A content data and material use plans.
- TFA uses HPF (Hyphal Pairing & Fusion), ceramic carriers, and batch testing to manage its sources of research material.
TFA Therapeutics, Inc. (OTCQB: RAJAF) provided an overview of upstream material supply and quality management for TFA-01. Based on the company's current production and testing data, cultured material supply capacity is approximately 100 kilograms per month. The company reports internal batches with consistent Antcin A content of at least 3,000 ppm on a dry-weight basis. This capacity will support formulation research and preparation of study materials.
The company uses HPF (Hyphal Pairing & Fusion) technology and screens strains for high Antcin A content. It combines ceramic carriers with controlled culture conditions and tracks Antcin A content in each material batch. Batch records guide extraction, preparation, and formulation research.
Antcin A is a naturally occurring active constituent of Antrodia cinnamomea. Formulation comparisons, repeated experiments, and safety evaluations require an ongoing supply of material. TFA's current cultivation capacity allows the company to plan its upstream material needs and verify content through batch testing, reducing reliance on research reagents purchased in small quantities.
The company will schedule purification, preparation of injectable formulations, and quality testing according to study requirements. Records of material sources, content, and preparation will be retained for traceability in subsequent research.
The 100-kilogram figure refers to cultured material, and 3,000 ppm describes its Antcin A content. These figures do not represent production capacity for purified active pharmaceutical ingredient or marketable injectable products.
About TFA
TFA Therapeutics, Inc. (OTCQB: RAJAF) is developing TFA-01, an Antcin A-based drug candidate, with canine osteoarthritis as its initial target indication. The program includes source material and formulation development, as well as safety and efficacy evaluation.
Forward-looking statements: The development plans described in this release may change in response to study results, regulatory requirements, and funding arrangements. Actual progress and outcomes may differ from current expectations.